Cell Regeneration Medicine Global Market Report 2024

The global cell regeneration medicine market has grown rapidly in recent years. It will grow from $36.08 billion in 2023 to $41.83 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to aging population, prevalence of chronic diseases, growing government and corporate funding, growing demand for functional regenerative medicine products.

The global cell regeneration medicine market is expected to see rapid growth in the next few years. It will grow to $71.86 billion in 2028 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to rising demand for regenerative medicine products from the horeca sector, shortage of organs for transplantation, increasing r&d activities, growing demand for gene therapies. Major trends in the forecast period include advanced therapies, clinical trial expansion, tissue engineering and 3d bioprinting, exosome-based therapies, personalized medicine.

The extensive adoption of organ transplantation is anticipated to drive the growth of the cell regeneration medicine market in the foreseeable future. Organ transplantation is a medical procedure involving the removal of an organ from one individual's body and its placement into the body of a recipient to replace a damaged or missing organ. This medical practice has gained significant popularity due to its ability to extend lives and reduce the need for interventions like dialysis. Cell regenerative medicine holds the promise of advancing organ transplantation by focusing on the repair and regeneration of damaged tissues or organs. For instance, in January 2023, as reported by the United Network for Organ Sharing, a US-based organization specializing in scientific and educational initiatives, the United States witnessed approximately 42,887 organ transplant procedures in 2022, marking a 3.7% increase compared to 2021. Consequently, the widespread acceptance of organ transplants is poised to be a driving force behind the cell regeneration medicine market.

The increasing incidence of chronic diseases is set to drive the growth of the cell regeneration medicine market in the foreseeable future. Chronic diseases encompass a range of long-lasting health conditions that persist for three months or more, often worsening over time. Cell regeneration medicine offers a promising avenue for addressing chronic diseases by pioneering innovative techniques to rejuvenate and restore damaged tissues and organs. It opens new horizons for research and therapies that have the potential to revolutionize the management and treatment of chronic illnesses. For instance, as of January 2023, data from the National Center for Biotechnology Information (NCBI), a division of the US National Library of Medicine, suggests that the global population living with chronic diseases is expected to rise to 142.66 million by the year 2050, a significant increase from the 71.522 million reported in 2020. Thus, the escalating prevalence of chronic diseases is a key driver behind the expansion of the cell regeneration medicine market.

The high cost of regenerative medicine therapies is anticipated to impede the growth of the cell regeneration medicine market in the forecast period. The elevated expenses associated with regenerative medicine treatments can be attributed to various factors, including the intricacies of the procedures involved in the collection and processing of therapeutic materials, the significant demand for stem cell therapies, and the increased costs linked to regulatory compliance. For example, as of September 2023, the Twin Cities Pain Clinic, a medical group practice based in the US, reported that stem cell treatments in the Minneapolis area typically range from $3,500 to $6,000. Additionally, DCV Stem, a US-based stem cell therapy clinic, estimated that the cost of stem cell therapy involving expanded cell products could range between $15,000 and $30,000 in 2023. Thus, the substantial expenses associated with regenerative medicine therapies serve as a hindrance to the cell regeneration medicine market's growth.

Leading companies operating within the cell regeneration medicine market are placing a growing emphasis on the development of innovative manufacturing techniques to gain a competitive advantage in the industry. Innovative manufacturing techniques encompass advanced and creative methods, processes, or technologies employed in the production of various goods and products. As an example, in June 2021, the RegenMed Development Organization (ReMDO), a non-profit foundation based in the United States, collaborated with the Wake Forest Institute for Regenerative Medicine (WFIRM) to introduce the RegeneratOR Test Bed. This pioneering initiative in regenerative medicine is designed to expedite the translation of scientific advancements into clinical applications by facilitating the scaling-up and automation of biomanufacturing processes.

In April 2022, Metcela Inc., a Japanese biotechnology firm with expertise in heart disease treatment, completed the acquisition of Japan Regenerative Medicine Co. Ltd. (JRM) for an undisclosed sum. This acquisition provides Metcela with the opportunity to diversify and enhance its product development portfolio through the addition of JRM-001. This innovative product utilizes cardiac stem cells to facilitate the restoration of cardiac tissues, particularly for the treatment of heart diseases. Japan Regenerative Medicine Co. Ltd. (JRM) is a Japanese biotechnology company primarily focused on the development of regenerative medicine solutions for heart diseases.

Major players in the cell regeneration medicine market are Pfizer Inc., Johnson & Johnson, F.Hoffman-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Medtronic PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., ViaCord LLC, Stryker Corporation, Zimmer Biomet Holdings Inc., Cook Biotech Inc., Integra LifeSciences Holdings Corporation, NuVasive Inc., Organogenesis Holdings Inc., AMAG Pharmaceuticals Inc., Takara Bio Inc., MiMedx Group Inc., Vericel Corporation, Mesoblast Limited, Osiris Therapeutics Inc., Guanhao Biotech Co. Ltd., CordLife Group Limited, FUJIFILM Cellular Dynamics Inc., Cesca Therapeutics Inc., U.S. Stem Cell Inc., Cytori Therapeutics Inc.

North America was the largest region in the cell regeneration medicine market in 2023. The regions covered in cell regeneration medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell regeneration medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The key components of cell regeneration medicine encompass therapeutics, tools, banks, and services. Therapeutics pertain to the medical treatment and care of patients with the objective of both preventing and managing diseases, alleviating pain or injury, and addressing conditions like injuries and diseases through methods such as immunomodulation therapy and tissue engineering. These therapeutics are classified into specific categories, including dermatology, musculoskeletal, immunology and inflammation, oncology, cardiovascular, ophthalmology, and others. They find application across various sectors, serving end-users like hospitals and clinics, commercial industries, government institutions, and academic research institutes.

The cell regeneration medicine research report is one of a series of new reports provides cell regeneration medicine market statistics, including the cell regeneration medicine global market size, regional shares, competitors with a cell regeneration medicine market share, detailed cell regeneration medicine market segments, market trends and opportunities and any further data you may need to thrive in the cell regeneration medicine industry. This cell regeneration medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell regeneration medicine market includes revenues earned by entities by providing stem cell treatments, cartilage regeneration, platelet-rich plasma and tissue engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell regeneration medicine market also includes of sales of various types of cell regeneration medicines, such as stem cells and progenitor cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.